

**MEDIA RELEASE**

**VivaZome presenting at 2021 American Society of Gene & Cell Therapy conference**

**11 May 2021; Melbourne Australia:** VivaZome Therapeutics Pty Ltd is pleased to announce that Chief Executive Officer Dr David Haylock is presenting at the Annual Conference of the American Society of Gene and Cell Therapy on 13 May 2021. Dr Haylock is delivering a substantial presentation entitled “Exosome manufacture in a fixed-bed bioreactor, and overcoming production challenges” in an Industrial Symposium sponsored by Pall Corporation.

The American Society of Gene & Cell Therapy (ASGCT) is a membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The ASGCT is the largest association of individuals involved in gene and cell therapy research, with 4,500 members in the United States and worldwide. At last year’s annual conference, 6,200 delegates attended in the ASGCT’s first-ever virtual environment. A strong response is also expected at the 2021 virtual conference (see <https://annualmeeting.asgct.org/>).

In addition, Dr Haylock will deliver a similar presentation in a BioPharma Asia webinar on 11 May 2021, again sponsored by Pall Corporation (see <https://biopharma-asia.com/>).

Dr Haylock stated: “VivaZome is delighted to be presenting at the prestigious ASGCT conference. We have undertaken a substantial body of experimental work in collaboration with Pall and we look forward to sharing our data and insights at this major meeting”

For further information, contact:

VivaZome Therapeutics Pty Ltd  
Dr David Haylock, CEO  
[David.haylock@vivazome.com](mailto:David.haylock@vivazome.com)  
Phone: +61 (0) 439 617 657

**About VivaZome Therapeutics Pty Ltd**

VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with operational headquarters at the La Trobe University Technology Enterprise Centre in Melbourne, Australia. VivaZome aims to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on ischaemia, fibrotic disease and neurological disorders.

VivaZome is developing new technologies and generating intellectual property and proprietary materials that are applicable generically to exosome therapies. These will underpin the Company’s development of specific exosome products for its target indications.

The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

For more information, please visit [www.vivazome.com](http://www.vivazome.com).